Freedom of Information Request: 0888 2020/21

We would greatly appreciate it if you could provide answers to the following questions.

Q1. How many adult and paediatric patients registered with your Haemophilia Centre suffer from the following conditions:

Please note the Trust’s Haemophilia Centre provides services for adults, not paediatric patients.

• Haemophilia A – 241
• Haemophilia B – 46
• Von Willebrand Disease – 366

Q2. In the last three months, how many patients have been treated with the following:

• Advate – 23
• Adynovi – 0
• Elocta – 6
• Esperoct – 0
• Factor Eight Inhibitor Bypass Activity (FEIBA) – 7
• Hemlibra – 21
• Jivi – 0
• NovoEight – 14
• NovoSeven RT – 6
• Obizur – 0
• Refacto AF – 25
• Alprolix – 8
• BeneFIX – 2
• Idelvion – 2
• Refixia – 0
• Rixubis – 0
• Gene therapy (for Haemophilia B) – 0
• DDAVP (desmopressin) – 3
• Tranexamic acid – not recorded
• Veyvondi – 0
• Voncento – 6
• Wilate – 3

Q3. Of the Haemophilia A patients treated in the last three months, could you please tell us the number of mild, moderate and severe patients.

• Mild – 6
• Moderate – 15
• Severe – 67          

Q4. Of the Haemophilia A patients treated in the last three months, could you please tell us the number of patients with and without Factor VIII Inhibitors.

• 4

Q5. Of the Haemophilia B patients treated in the last three months, could you please tell us the number of mild, moderate and severe patients.

• Mild – 1
• Moderate – 1
• Severe – 11